• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer.

作者信息

Rossi Alexander J, Khan Tahsin M, Hong Hanna, Lesinski Gregory B, Wu Christina, Hernandez Jonathan M

机构信息

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA.

出版信息

Ann Surg Oncol. 2021 Aug;28(8):4098-4099. doi: 10.1245/s10434-021-10111-0. Epub 2021 May 13.

DOI:10.1245/s10434-021-10111-0
PMID:33987757
Abstract
摘要

相似文献

1
Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer.培匹奈单抗（抗SEMA4D）联合伊匹木单抗或纳武单抗用于可切除胰腺癌和结直肠癌患者。
Ann Surg Oncol. 2021 Aug;28(8):4098-4099. doi: 10.1245/s10434-021-10111-0. Epub 2021 May 13.
2
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.纳武利尤单抗联合伊匹单抗治疗错配修复缺陷/微卫星高度不稳定转移性结直肠癌的持久临床获益。
J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
3
[Drug Approval: Nivolumab plus ipilimumab for patients with MSI -high metastatic colorectal cancer previously treated with 5-fluorouracilchemotherapy].[药物批准：纳武利尤单抗联合伊匹木单抗用于既往接受过5-氟尿嘧啶化疗的微卫星高度不稳定转移性结直肠癌患者]
Bull Cancer. 2022 Jan;109(1):3-4. doi: 10.1016/j.bulcan.2021.08.010. Epub 2021 Oct 29.
4
Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.二线伊匹单抗与纳武单抗联合伊匹单抗在接受一线抗PD-1抗体治疗的晚期黑色素瘤患者中的疗效比较。
J Oncol Pharm Pract. 2021 Apr;27(3):555-559. doi: 10.1177/1078155220924719. Epub 2020 May 19.
5
Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.接受伊匹单抗和纳武利尤单抗联合治疗或单药治疗的患者的胃肠道并发症。
J Comp Eff Res. 2019 Jan;8(2):81-90. doi: 10.2217/cer-2018-0072. Epub 2018 Dec 14.
6
Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?谁应接受纳武利尤单抗联合伊匹木单抗的免化疗方案作为晚期非小细胞肺癌的一线治疗？
J Clin Oncol. 2023 Feb 20;41(6):1172-1175. doi: 10.1200/JCO.22.02278. Epub 2023 Jan 9.
7
[Efficacy and Management of Adverse Events of Ipilimumab Including Combination Therapy with Nivolumab].伊匹单抗的疗效及不良事件管理，包括与纳武单抗联合治疗
Gan To Kagaku Ryoho. 2019 Jun;46(6):1017-1026.
8
Ipilimumab and Nivolumab for Treatment of Eyelid Spindle Cell Melanoma.伊匹单抗和纳武单抗治疗眼睑梭形细胞黑色素瘤
Am J Ophthalmol. 2023 Jun;250:e1-e2. doi: 10.1016/j.ajo.2023.02.010. Epub 2023 Feb 18.
9
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.纳武利尤单抗联合或不联合伊匹单抗治疗转移性肉瘤（Alliance A091401）：两项开放标签、非比较、随机、2 期临床试验。
Lancet Oncol. 2018 Mar;19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Epub 2018 Jan 19.
10
Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy.纳武利尤单抗联合伊匹单抗治疗后长期抗肿瘤疗效相关的严重坏死性肌炎。
Clin Rheumatol. 2019 Feb;38(2):601-602. doi: 10.1007/s10067-018-4373-y. Epub 2018 Nov 19.

引用本文的文献

1
Constructing the cure: engineering the next wave of antibody and cellular immune therapies.构建治愈方法：打造下一代抗体和细胞免疫疗法。
J Immunother Cancer. 2025 Aug 25;13(8):e011761. doi: 10.1136/jitc-2025-011761.
2
[New therapeutic approaches in the neoadjuvant/adjuvant treatment of melanoma].[黑色素瘤新辅助/辅助治疗中的新治疗方法]
Dermatologie (Heidelb). 2025 Jun;76(6):354-360. doi: 10.1007/s00105-025-05508-x. Epub 2025 May 23.
3
Updates in Immunotherapy for Pancreatic Cancer.胰腺癌免疫治疗的进展
J Clin Med. 2024 Oct 26;13(21):6419. doi: 10.3390/jcm13216419.
4
Associations of SEMA7A, SEMA4D, ADAMTS10, and ADAM8 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, Microsatellite Instability Status, and Cytokine Expression in Colorectal Cancer Tissue.SEMA7A、SEMA4D、ADAMTS10和ADAM8与结直肠癌组织中KRAS、NRAS、BRAF、PIK3CA和AKT基因突变、微卫星不稳定性状态及细胞因子表达的相关性
Curr Issues Mol Biol. 2024 Sep 15;46(9):10218-10248. doi: 10.3390/cimb46090609.
5
Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results.局部胰腺癌的新辅助免疫治疗：挑战与早期结果
Cancers (Basel). 2023 Aug 4;15(15):3967. doi: 10.3390/cancers15153967.
6
Mediating immunosuppressive functions: a new perspective on the complex immunological properties of SEMA4D in the tumor microenvironment.介导免疫抑制功能：肿瘤微环境中SEMA4D复杂免疫学特性的新视角。
Front Oncol. 2023 May 23;13:1171926. doi: 10.3389/fonc.2023.1171926. eCollection 2023.
7
γδ T cell costimulatory ligands in antitumor immunity.抗肿瘤免疫中的γδ T细胞共刺激配体
Explor Immunol. 2022;2(1):79-97. doi: 10.37349/ei.2022.00038. Epub 2022 Feb 24.
8
Differential Effects on the Translation of Immune-Related Alternatively Polyadenylated mRNAs in Melanoma and T Cells by eIF4A Inhibition.eIF4A抑制对黑色素瘤和T细胞中免疫相关可变聚腺苷酸化mRNA翻译的不同影响。
Cancers (Basel). 2022 Feb 24;14(5):1177. doi: 10.3390/cancers14051177.